CAMBRIDGE, Mass., March 21 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPUR) announced today that it has received notification from The
Nasdaq Stock Market that the company has regained compliance with the $1.00
minimum bid price requirement for continued listing on the Nasdaq National
Market, pursuant to Marketplace Rule 4450(a)(5).
Biopure Corporation
Biopure Corporation develops, manufactures and markets pharmaceuticals,
called oxygen therapeutics, that are intravenously administered to deliver
oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer -- 250
(bovine)], or HBOC-201, is approved for sale in South Africa for the treatment
of surgical patients who are acutely anemic. The product has not been
approved for sale in other countries. Biopure plans to apply in Europe, in
mid 2006, for approval of an acute anemia indication in orthopedic surgery
patients. The company is developing Hemopure for a potential indication in
cardiovascular ischemia, in addition to supporting the U.S. Naval Medical
Research Center's government-funded development of a potential out-of-hospital
trauma indication. The company's veterinary product Oxyglobin(R) [hemoglobin
glutamer -- 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved
by the U.S. Food and Drug Administration and the European Commission, is
indicated for the treatment of anemia in dogs.
Contact: Douglas Sayles
Biopure Corporation
(617) 234-6826
IR@biopure.com
SOURCE Biopure Corporation
 back to top
Related links:
http://www.biopure.com
Company News On-Call:
http://www.prnewswire.com/comp/131224.html
CONTACT:
Douglas Sayles of Biopure Corporation,
+1-617-234-6826, IR@biopure.com
|
